Belantamab Mafodotin Combos Show Promise in Relapsed Multiple Myeloma Trial
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
20 articles
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Swiss researchers completed a 74-patient phase 2 trial exploring optimal dosing schedules for dual checkpoint blockade in metastatic renal cell carcinoma.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.